Table 4

Sensitivity analysis—impact of number of intravesical administration of HA+CS on clinical outcomes

Bacteriologically confirmed recurrenceOR (95% CI)Adjusted* OR (95% CI)
≥5 Instillations (n=156) vs standard of care0.81 (0.48 to 1.36)0.52 (0.27 to 0.99)
≥6 Instillations (n=134) vs standard of care0.69 (0.40 to 1.18)0.47 (0.25 to 0.91)
≥7 Instillations (n=82) vs standard of care0.63 (0.34 to 1.14)0.43 (0.21 to 0.88)
Total number of bacteriologically confirmed recurrenceIRR (95% CI)Adjusted* IRR (95% CI)
≥5 Instillations vs standard of care1.82 (1.33 to 2.49)1.05 (0.73 to 1.52)
≥6 Instillations vs standard of care1.64 (1.18 to 2.28)0.97 (0.66 to 1.40)
≥7 Instillations vs standard of care1.46 (1 to 2.13)0.90 (0.60 to 1.36)
Time to first bacteriologically confirmed recurrenceHR (95% CI)Adjusted* HR (95% CI)
≥5 Instillations vs standard of care1.72 (1.12 to 2.65)1.04 (0.64 to 1.71)
≥6 Instillations vs standard of care1.55 (0.99 to 2.41)0.96 (0.58 to 1.57)
≥7 Instillations vs standard of care1.33 (0.79 to 2.22)0.85 (0.49 to 1.47)
  • *Adjusted for age, BMI, employment and menopause status, postcoital infections, dyspareunia, FSFI and severity of RUTI.

  • BMI, body mass index; FSFI, Female Sexual Function Index; HA+CS, hyaluronic acid and chondroitin sulfate; IRR, incidence rate ratio; RUTI, recurrent urinary tract infection.